Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABBV 
AbbVie Inc (ABBV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ABBV (3-star) is a STRONG-BUY. BUY since 47 days. Simulated Profits (16.29%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
28 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $221.74
1 Year Target Price $221.74
| 12 | Strong Buy |
| 4 | Buy |
| 12 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 27.58% | Avg. Invested days 46 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 382.04B USD | Price to earnings Ratio 102.98 | 1Y Target Price 221.74 |
Price to earnings Ratio 102.98 | 1Y Target Price 221.74 | ||
Volume (30-day avg) 28 | Beta 0.53 | 52 Weeks Range 159.42 - 221.77 | Updated Date 09/17/2025 |
52 Weeks Range 159.42 - 221.77 | Updated Date 09/17/2025 | ||
Dividends yield (FY) 2.97% | Basic EPS (TTM) 2.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.45% | Operating Margin (TTM) 37.52% |
Management Effectiveness
Return on Assets (TTM) 8.87% | Return on Equity (TTM) 112.85% |
Valuation
Trailing PE 102.98 | Forward PE 15.48 | Enterprise Value 448434741435 | Price to Sales(TTM) 6.55 |
Enterprise Value 448434741435 | Price to Sales(TTM) 6.55 | ||
Enterprise Value to Revenue 7.69 | Enterprise Value to EBITDA 31.66 | Shares Outstanding 1766560000 | Shares Floating 1762954474 |
Shares Outstanding 1766560000 | Shares Floating 1762954474 | ||
Percent Insiders 0.1 | Percent Institutions 74.6 |
Upturn AI SWOT
AbbVie Inc
Company Overview
History and Background
AbbVie Inc. was founded in 2013 as a spin-off from Abbott Laboratories. It focuses on developing and marketing pharmaceutical products.
Core Business Areas
- Immunology: Focuses on treatments for autoimmune diseases like rheumatoid arthritis, Crohn's disease, and psoriasis. Key products include Humira, Rinvoq, and Skyrizi.
- Oncology: Develops therapies for various cancers, including hematologic malignancies and solid tumors. Key products include Imbruvica and Venclexta.
- Neuroscience: Focuses on treatments for neurological disorders like Parkinson's disease and migraines. Key products include Botox Therapeutic (migraine) and Ubrelvy.
- Eye Care: Develops treatments for eye conditions like dry eye disease and glaucoma. Key products include Restasis and Lumigan.
Leadership and Structure
AbbVie is led by CEO Richard A. Gonzalez. The company has a hierarchical structure with various divisions reporting to executive leadership.
Top Products and Market Share
Key Offerings
- Humira (adalimumab): A TNF inhibitor used to treat autoimmune diseases. Once AbbVie's top seller. Facing biosimilar competition. Competitors: Amgen (Amjevita), Sandoz (Hyrimoz), Biogen (Biosimiliars)
- Skyrizi (risankizumab): An interleukin-23 (IL-23) inhibitor used to treat psoriasis and Crohn's disease. Strong growth potential. Competitors: Johnson & Johnson (Tremfya), Novartis (Cosentyx).
- Rinvoq (upadacitinib): A JAK inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions. Competitors: Pfizer (Xeljanz), Eli Lilly (Olumiant).
- Imbruvica (ibrutinib): A BTK inhibitor used to treat certain blood cancers. Sales have been declining due to competition. Competitors: AstraZeneca (Calquence), BeiGene (Brukinsa).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Patent expirations and biosimilar/generic entry pose significant challenges.
Positioning
AbbVie is a major player in the pharmaceutical industry, with a strong presence in immunology, oncology, and neuroscience. Its competitive advantages include a diversified product portfolio, robust pipeline, and strong marketing capabilities.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1 trillion. AbbVie is well-positioned to capture a significant share of this market, particularly in its core therapeutic areas.
Upturn SWOT Analysis
Strengths
- Strong product portfolio
- Robust pipeline of potential new drugs
- Experienced management team
- Strong marketing and distribution capabilities
- High profitability
Weaknesses
- Reliance on Humira (diminishing due to biosimilar competition)
- Exposure to patent expirations
- High debt levels (due to Allergan acquisition)
- Regulatory risks
- Integration risks from acquisitions
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions and partnerships
- Growth in emerging markets
- Development of innovative therapies
- Digital health and personalized medicine
Threats
- Biosimilar competition
- Generic drug competition
- Pricing pressures
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- NVS
- BMY
Competitive Landscape
AbbVie faces intense competition from other major pharmaceutical companies. Its ability to maintain market share depends on its ability to innovate and commercialize new products.
Major Acquisitions
Allergan
- Year: 2020
- Acquisition Price (USD millions): 63000
- Strategic Rationale: Diversified AbbVie's product portfolio and reduced reliance on Humira. Added Botox and other aesthetic products.
Growth Trajectory and Initiatives
Historical Growth: AbbVie has experienced significant growth driven by Humira sales and strategic acquisitions. Future growth will depend on the success of its pipeline and ability to offset Humira's decline.
Future Projections: Analyst estimates vary, but project continued growth driven by Skyrizi, Rinvoq and new product launches. Biosimilar competition and pricing pressures remain key challenges.
Recent Initiatives: Recent initiatives include acquisitions of smaller biotech companies and investments in research and development. Focusing on expansion of pipeline and key products.
Summary
AbbVie is a major pharmaceutical company with a strong product portfolio, particularly in immunology. The loss of exclusivity for Humira poses a significant challenge, but new products like Skyrizi and Rinvoq are driving growth. AbbVie's large acquisition of Allergan adds breadth but also increased debt. AbbVie needs to successfully launch new drugs and navigate competitive pressures to maintain its financial performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Financial Reports
- Analyst Reports
- Industry Publications
- SEC Filings
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change, and investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AbbVie Inc
Exchange NYSE | Headquaters North Chicago, IL, United States | ||
IPO Launch date 2013-01-02 | CEO & Chairman of the Board Mr. Robert A. Michael CPA | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 55000 | Website https://www.abbvie.com |
Full time employees 55000 | Website https://www.abbvie.com | ||
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.